S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:CERS

Cerus - CERS Stock Forecast, Price & News

$3.01
-0.11 (-3.53%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.00
$3.14
50-Day Range
$2.72
$4.22
52-Week Range
$2.53
$6.00
Volume
1.03 million shs
Average Volume
1.69 million shs
Market Capitalization
$534.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Cerus MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
62.0% Upside
$4.88 Price Target
Short Interest
Bearish
3.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of Cerus in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$48,875 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

783rd out of 1,055 stocks

Surgical & Medical Instruments Industry

78th out of 106 stocks


CERS stock logo

About Cerus (NASDAQ:CERS) Stock

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

BTIG Research Lowers Cerus (NASDAQ:CERS) to Neutral
Cerus (NASDAQ:CERS) Downgraded by BTIG Research
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Cerus's Return On Capital Employed Overview
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Cerus (NASDAQ: CERS)
Cerus Corporation (CERS)
See More Headlines
Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
2/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:CERS
CUSIP
15708510
Employees
631
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.75
Forecasted Upside/Downside
+62.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-54,380,000.00
Pretax Margin
-24.09%

Debt

Sales & Book Value

Annual Sales
$130.86 million
Book Value
$0.50 per share

Miscellaneous

Free Float
164,416,000
Market Cap
$534.03 million
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Obi Greenman
    President, Chief Executive Officer & Director
  • Vivek K. JayaramanVivek K. Jayaraman
    Chief Operating Officer
  • Kevin Dennis GreenKevin Dennis Green
    Chief Financial Officer & Vice President-Finance
  • Laurence M. CorashLaurence M. Corash
    Chief Scientific Officer
  • Carol M. MooreCarol M. Moore
    Senior VP-Regulatory Affairs, Quality & Clinical













CERS Stock - Frequently Asked Questions

Should I buy or sell Cerus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings
or view top-rated stocks.

What is Cerus' stock price forecast for 2023?

3 Wall Street analysts have issued 12 month target prices for Cerus' shares. Their CERS share price forecasts range from $3.75 to $6.00. On average, they predict the company's stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price.
View analysts price targets for CERS
or view top-rated stocks among Wall Street analysts.

How have CERS shares performed in 2023?

Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS shares have decreased by 17.5% and is now trading at $3.01.
View the best growth stocks for 2023 here
.

Are investors shorting Cerus?

Cerus saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,280,000 shares, an increase of 11.7% from the December 31st total of 5,620,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is presently 4.8 days.
View Cerus' Short Interest
.

When is Cerus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our CERS earnings forecast
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The biotechnology company earned $39.57 million during the quarter, compared to analysts' expectations of $39 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million.

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (8.94%), Sumitomo Mitsui Trust Holdings Inc. (4.04%), Assenagon Asset Management S.A. (1.41%), Stephens Inc. AR (0.36%), Rice Hall James & Associates LLC (0.31%) and Exchange Traded Concepts LLC (0.14%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends
.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $3.01.

How much money does Cerus make?

Cerus (NASDAQ:CERS) has a market capitalization of $534.03 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Cerus have?

The company employs 631 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 1/31/2023 by MarketBeat.com Staff